{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T22:46:02Z","timestamp":1775947562420,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Korea United Pharm. Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s40261-023-01302-6","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T19:02:57Z","timestamp":1693508577000},"page":"729-738","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Safety and Effectiveness of Controlled-Release Cilostazol in Patients with Symptomatic Peripheral Artery Disease"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9495-7182","authenticated-orcid":false,"given":"Woo-young","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-9787","authenticated-orcid":false,"given":"Hye Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7630-9501","authenticated-orcid":false,"given":"Jung-ha","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"1302_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nrcardio.2016.179","volume":"14","author":"FG Fowkes","year":"2017","unstructured":"Fowkes FG, Aboyans V, Fowkes FJ, McDermott MM, Sampson UK, Criqui MH. Peripheral artery disease: epidemiology and global perspectives. Nat Rev Cardiol. 2017;14:156\u201370. https:\/\/doi.org\/10.1038\/nrcardio.2016.179.","journal-title":"Nat Rev Cardiol."},{"key":"1302_CR2","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMcp1507631","volume":"374","author":"IJ Kullo","year":"2016","unstructured":"Kullo IJ, Rooke TW. Clinical practice. Peripheral artery disease. N Engl J Med. 2016;374:861\u201371. https:\/\/doi.org\/10.1056\/NEJMcp1507631.","journal-title":"N Engl J Med"},{"key":"1302_CR3","doi-asserted-by":"publisher","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators.\u00a0Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789\u20131858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"issue":"2","key":"1302_CR4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/jpm13020316","volume":"13","author":"E Martelli","year":"2023","unstructured":"Martelli E, Zamboni M, Sotgiu G, Saderi L, Federici M, Sangiorgi GM, et al. Sex-related differences and factors associated with peri-procedural and 1 year mortality in chronic limb-threatening ischemia patients from the CLIMATE Italian Registry. J Pers Med. 2023;13(2):316. https:\/\/doi.org\/10.3390\/jpm13020316.","journal-title":"J Pers Med."},{"key":"1302_CR5","first-page":"443","volume":"14","author":"RM Schainfeld","year":"2001","unstructured":"Schainfeld RM. Management of peripheral arterial disease and intermittent claudication. J Am Board Fam Pract. 2001;14:443\u201350.","journal-title":"J Am Board Fam Pract"},{"key":"1302_CR6","doi-asserted-by":"publisher","first-page":"e726","DOI":"10.1161\/CIR.0000000000000471","volume":"135","author":"MD Gerhard-Herman","year":"2017","unstructured":"Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, et al. 2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135:e726\u201379. https:\/\/doi.org\/10.1161\/CIR.0000000000000471.","journal-title":"Circulation"},{"key":"1302_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000138400","volume":"36","author":"T Tanaka","year":"1988","unstructured":"Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology. 1988;36:313\u201320. https:\/\/doi.org\/10.1159\/000138400.","journal-title":"Pharmacology"},{"key":"1302_CR8","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1161\/ATVBAHA.108.164368","volume":"28","author":"H Ota","year":"2008","unstructured":"Ota H, Eto M, Kano MR, Ogawa S, Iijima K, Akishita M, et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler Thromb Vasc Biol. 2008;28:1634\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.108.164368.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1302_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12020-017-1279-4","volume":"56","author":"NJ Asal","year":"2017","unstructured":"Asal NJ, Wojciak KA. Effect of cilostazol in treating diabetes-associated microvascular complications. Endocrine. 2017;56:240\u20134. https:\/\/doi.org\/10.1007\/s12020-017-1279-4.","journal-title":"Endocrine"},{"key":"1302_CR10","unstructured":"ClinCalc. Cilostazol\u2014drug usage statistics. https:\/\/clincalc.com\/DrugStats\/Drugs\/Cilostazol. Accessed 31 Jul 2023."},{"key":"1302_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1177\/1538574413518121","volume":"48","author":"C Lee","year":"2014","unstructured":"Lee C, Nelson PR. Effect of cilostazol prescribed in a pragmatic treatment program for intermittent claudication. Vasc Endovascular Surg. 2014;48:224\u20139. https:\/\/doi.org\/10.1177\/1538574413518121.","journal-title":"Vasc. Endovascular Surg."},{"key":"1302_CR12","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/jphp.12227","volume":"66","author":"KH Shin","year":"2014","unstructured":"Shin KH, Yoon G, Yoon IS, Park JW. Preparation and evaluation of oral controlled-release cilostazol formulation: pharmacokinetics and antithrombotic efficacy in dogs and healthy male Korean participants. J Pharm Pharmacol. 2014;66:961\u201374. https:\/\/doi.org\/10.1111\/jphp.12227.","journal-title":"J Pharm Pharmacol"},{"key":"1302_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.12793\/tcp.2016.24.4.183","volume":"24","author":"JD Son","year":"2016","unstructured":"Son JD, Cho SM, Choi YW, Kim SH, Kwon IS, Jin EH, et al. Pharmacokinetic characteristics of cilostazol 200 mg controlled-release tablet compared with two cilostazol 100 mg immediate-release tablets (Pletal) after single oral dose in healthy Korean male volunteers. Transl Clin Pharmacol. 2016;24:183\u20138.","journal-title":"Transl Clin Pharmacol."},{"key":"1302_CR14","unstructured":"Common Terminology Criteria for Adverse Event (CTCAE) v5.0. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf. 2017. Accessed 30 Jul 2023."},{"key":"1302_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2008.04.019","volume":"20","author":"HS Rehan","year":"2009","unstructured":"Rehan HS, Chopra D, Kakkar AK. Physician\u2019s guide to pharmacovigilance: terminology and causality assessment. Eur J Intern Med. 2009;20:3\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2008.04.019.","journal-title":"Eur J Intern Med"},{"key":"1302_CR16","unstructured":"World Health Organization-Uppsala Monitoring Center. The WHO Adverse Reaction Terminology (WHO-ART). http:\/\/www.umc-products.com\/DynPage.aspx?id=73589&mn1=1107&mn2=1664. 2005. Accessed 23 Aug 2021."},{"key":"1302_CR17","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1161\/01.cir.98.7.678","volume":"98","author":"DL Dawson","year":"1998","unstructured":"Dawson DL, Cutler BS, Meissner MH, Strandness DE. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678\u201386. https:\/\/doi.org\/10.1161\/01.cir.98.7.678.","journal-title":"Circulation"},{"key":"1302_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/153857440203600202","volume":"36","author":"DE Strandness Jr","year":"2002","unstructured":"Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovascular Surg. 2002;36:83\u201391. https:\/\/doi.org\/10.1177\/153857440203600202.","journal-title":"Vasc. Endovascular Surg."},{"key":"1302_CR19","doi-asserted-by":"publisher","unstructured":"Money SR, Herd JA, Isaacsohn JL, Davidson M, Cutler B, Heckman J et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J. Vasc. Surg. 1998;27:267\u2013274. https:\/\/doi.org\/10.1016\/s0741-5214(98)70357-x(discussion 274\u2013275).","DOI":"10.1016\/s0741-5214(98)70357-x"},{"key":"1302_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jvs.2007.10.009","volume":"47","author":"WR Hiatt","year":"2008","unstructured":"Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008;47:330\u20136. https:\/\/doi.org\/10.1016\/j.jvs.2007.10.009.","journal-title":"J Vasc Surg"},{"key":"1302_CR21","doi-asserted-by":"publisher","first-page":"408","DOI":"10.5414\/CP203434","volume":"57","author":"W Shin","year":"2019","unstructured":"Shin W, Kim MK, Cho DY. Pharmacokinetic study of two extended-release formulations of cilostazol in healthy Korean subjects: A randomized, open-label, multiple-dose, two-period crossover study. Int J Clin Pharmacol Ther. 2019;57:408\u201315. https:\/\/doi.org\/10.5414\/CP203434.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1302_CR22","unstructured":"U.S. National Institutes of Health. Pletaal SR. Post Marketing Observational Study (PLTSRPMOS) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01782833. 2019. Accessed 30 Jul 2023."},{"key":"1302_CR23","unstructured":"International Angiology. Torino, Italy. 34 (1, 4), 7. Interim report of CILOPA trial: the efficacy of advanced cilostazol (Cilostan CR) in symptomatic peripheral artery disease. http:\/\/uip2015.org\/UIP%20Chapter%20Meeting%20-%20Seoul%20UIP%202015.pdf. 2015. Accessed 30 Jul 2023."},{"key":"1302_CR24","doi-asserted-by":"crossref","unstructured":"Bedenis R, Stewart M, Cleanthis M, Robless P, Mikhailidis DP, Stansby G. Cilostazol for intermittent claudication. Cochrane Database Syst Rev. CD003748; 2014.","DOI":"10.1002\/14651858.CD003748.pub4"},{"key":"1302_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s0002-9343(00)00569-6","volume":"109","author":"DL Dawson","year":"2000","unstructured":"Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523\u201330. https:\/\/doi.org\/10.1016\/s0002-9343(00)00569-6.","journal-title":"Am J Med"},{"key":"1302_CR26","doi-asserted-by":"publisher","first-page":"28D","DOI":"10.1016\/s0002-9149(01)01719-2","volume":"87","author":"CM Pratt","year":"2001","unstructured":"Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol. 2001;87:28D-33D. https:\/\/doi.org\/10.1016\/s0002-9149(01)01719-2.","journal-title":"Am J Cardiol"},{"key":"1302_CR27","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1093\/brain\/awu244","volume":"137","author":"S Guo","year":"2014","unstructured":"Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain. 2014;137:2951\u20139. https:\/\/doi.org\/10.1093\/brain\/awu244.","journal-title":"Brain"},{"key":"1302_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s10194-018-0841-7","volume":"19","author":"K Falkenberg","year":"2018","unstructured":"Falkenberg K, Dunga B\u00d3\u00c1, Guo S, Ashina M, Olesen J. Cilostazol induced migraine does not respond to sumatriptan in a double-blind trial. J Headache Pain. 2018;19:11. https:\/\/doi.org\/10.1186\/s10194-018-0841-7.","journal-title":"J Headache Pain"},{"key":"1302_CR29","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1111\/j.1468-2982.2006.01218.x","volume":"26","author":"S Birk","year":"2006","unstructured":"Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006;26:1304\u20139. https:\/\/doi.org\/10.1111\/j.1468-2982.2006.01218.x.","journal-title":"Cephalalgia"},{"key":"1302_CR30","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.12.002","volume":"24","author":"L Tan","year":"2015","unstructured":"Tan L, Margaret B, Zhang JH, Hu R, Yin Y, Cao L, et al. Efficacy and safety of cilostazol therapy in ischemic stroke: a meta-analysis. J Stroke Cerebrovasc Dis. 2015;24:930\u20138. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2014.12.002.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"1302_CR31","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.jacc.2011.06.023","volume":"58","author":"CL Wassel","year":"2011","unstructured":"Wassel CL, Loomba R, Ix JH, Allison MA, Denenberg JO, Criqui MH. Family history of peripheral artery disease is associated with prevalence and severity of peripheral artery disease: the San Diego population study. J Am Coll Cardiol. 2011;58:1386\u201392. https:\/\/doi.org\/10.1016\/j.jacc.2011.06.023.","journal-title":"J Am Coll Cardiol"},{"key":"1302_CR32","doi-asserted-by":"publisher","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","volume":"7","author":"P Song","year":"2019","unstructured":"Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health. 2019;7:e1020\u201330. https:\/\/doi.org\/10.1016\/S2214-109X(19)30255-4.","journal-title":"Lancet Glob Health"},{"key":"1302_CR33","doi-asserted-by":"publisher","unstructured":"Kalantzi K. Tentolouris N, Melidonis AJ, Papadaki S, Peroulis M, Amantos KA et al. Efficacy and safety of adjunctive cilostazol to clopidogrel-treated diabetic patients with symptomatic lower extremity artery disease in the prevention of ischemic vascular events. J Am Heart Assoc. 2021;10:e018184. https:\/\/doi.org\/10.1161\/JAHA.120.018184.","DOI":"10.1161\/JAHA.120.018184"},{"key":"1302_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4172\/2329-6607.1000133","volume":"4","author":"HB Chen","year":"2015","unstructured":"Chen HB, Zhang X, Liang H, Liu X, Xiu J. Cilostazol added to dual antiplatelet therapy for patients with high risk of restenosis after drug-eluting stent implantation: a systematic review and meta-analysis of RCTs. Cardiol Pharmacol. 2015;4:133. https:\/\/doi.org\/10.4172\/2329-6607.1000133.","journal-title":"Cardiol. Pharmacol."},{"key":"1302_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12933-018-0781-1","volume":"17","author":"M Nativel","year":"2018","unstructured":"Nativel M, Potier L, Alexandre L, Baillet-Blanco L, Ducasse E, Velho G, et al. Lower extremity arterial disease in patients with diabetes: a contemporary narrative review. Cardiovasc Diabetol. 2018;17:138. https:\/\/doi.org\/10.1186\/s12933-018-0781-1.","journal-title":"Cardiovasc Diabetol"},{"key":"1302_CR36","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/j.jacc.2005.09.065","volume":"47","author":"SP Marso","year":"2006","unstructured":"Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.065.","journal-title":"J Am Coll Cardiol"},{"key":"1302_CR37","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","volume":"320","author":"J Corrigan-Curay","year":"2018","unstructured":"Corrigan-Curay J, Sacks L, Woodcock J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. JAMA. 2018;320:867\u20138. https:\/\/doi.org\/10.1001\/jama.2018.10136.","journal-title":"JAMA"},{"key":"1302_CR38","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s12325-018-0805-y","volume":"35","author":"L Blonde","year":"2018","unstructured":"Blonde L, Khunti K, Harris SB, Meizinger C, Skolnik NS. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018;35:1763\u201374. https:\/\/doi.org\/10.1007\/s12325-018-0805-y.","journal-title":"Adv Ther"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-023-01302-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-023-01302-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:36:13Z","timestamp":1695353773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-023-01302-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1302"],"URL":"https:\/\/doi.org\/10.1007\/s40261-023-01302-6","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"assertion":[{"value":"16 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Korea United Pharm. Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the institutional review board of Seoul National University Hospital and Soon Chun Hyang University Bucheon Hospital (ref: 2015-085-665 and SCHBC 2014-07-036, 31 Oct 2013) and was conducted in accordance with the Good Clinical Practice guidelines as well as the principles evinced in the Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all individual participants for their inclusion in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The participants provided written informed consent for the publication of their data.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and analysed during the current study are not publicly available due to privacy concerns for subjects but are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualisation, Methodology, Visualization: J.H.K. Writing-Original draft preparation: W.Y.S. and H.J.L. Validation, Formal analysis, Investigation, Resources, Data curation, Writing-Review & editing, Supervision, Project administration: W.Y.S., H.J.L. and J.H.K. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}